# OnCo record paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018" ;
  schema:name "CheckMate 205: nivolumab for relapsed or refractory classical Hodgkin lymphoma after autologous transplant failure, extended follow-up"@en ;
  schema:description "The PD-1 antibody nivolumab produced responses in about seven in ten patients whose Hodgkin lymphoma had returned after a stem cell transplant, with responses lasting well over a year, confirming the exquisite sensitivity of this lymphoma to checkpoint blockade."@en ;
  schema:url <https://onco.cc/key-papers/paper-checkmate-205-nivolumab-rr-hodgkin-extended-follow-up-jco-2018/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2017.76.0793>, <https://pubmed.ncbi.nlm.nih.gov/29584546/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.2017.76.0793> ;
  schema:datePublished "2018"^^xsd:gYear ;
  schema:author "Armand P, Engert A, Younes A, et al." ;
  onco:cancers <https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> ;
  onco:trials <https://onco.cc/trials/checkmate-205/> ;
  onco:journals <https://onco.cc/journals/jco/> .